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(5.574 exposed and 14.596 not-exposed) were submitted to residential registries. 
The vital status of 96,6% of the study subjects could be confirmed by information 
of the registries. 80,7% were still alive 15 years after the accident (81% exposed, 80% 
not-exposed). 24,6% had died from cancer, 40,9% from cardiovascular diseases and 
31,8% from other causes of death. No effects of the exposure on the vital status 
could be determined (Cox-Regression). In the pharmacoepidemiological case study 
evaluating long term safety of hormone replacement therapy, the survival status of 
2.485 participants was investigated in country-wide residential databases. The vital 
status of 90,8% these participants could be confirmed using the registry information. 
2.250 were still alive after 4-5 years of inclusion into the study, only 6 deaths were 
identified and for only 9% the status could not be determined. ConClusions: 
Official residential registries can be a valuable source for investigating the survival 
status and the causes of death of study subjects in pharmaco- and general epide-
miological studies.
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objeCtives: Myelofibrosis (MF) is a chronic blood cancer with an estimated prev-
alence in the US population of 4-5 patients per 100.000 inhabitants. Among the 
sources to recruit MF patients for post-approval studies in a real life environment, 
oncological or cardiological sites are of primary importance. The objective of the 
present contribution is to assess the number of MF patients in these specialties 
and the willingness of the physicians to enroll MF patients for clinical and health 
outcomes studies. Methods: In 2011, a feasibility survey assessing the incidence 
of MF patients in the sites of 94 oncologists, 72 hematologists and 65 cardiologists in 
5 EU countries (UK, GER, FR, IT, ES) was run, using the All Global managed physician 
panel. The willingness of these specialist groups to participate in clinical and health 
outcomes studies and to recruit patients for these studies was estimated among 
335 oncologists/hematologists and 208 cardiologists. Results: 88% of the oncolo-
gists and 99% of the hematologists treat Myelofibrosis patients (88% oncologists; 
99% hematologists). Cardiologists are involved in MF treatment to a smaller degree 
(75%). In 25% of all practices, less than 10 patients are treated per year, in 36%, 11 
to 50 patients, and in 38%, more than 50. Approximately 90% of the oncologists/
hematologists and 88% of the cardiologists are experienced in clinical and health 
outcomes studies; 80% of the oncologists/hematologists and 60% of the cardiolo-
gists are willing to participate in future studies and 92% resp. 94% in this group 
are willing to enroll patients for clinical and health outcome studies, including 
management of informed consent and ethics procedures as required for the study 
type. ConClusions: Myelofibrosis patients can be successfully recruited for clini-
cal and health outcomes studies using managed panels. Oncologists/hematologists 
and cardiologists are experienced in these study types and willing to participate 
in future studies.
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objeCtives: Gastric cancer (GC) is a cancer arising from parts of the stomach. To 
recruit GC patients for post-approval studies in a real world environment, oncologi-
cal, hematological, and internist sites might be of primary importance. The present 
contribution assesses the number of GC patients in these sites and the willingness 
of physicians to enroll GC patients for health outcome or clinical phase III/IV studies. 
Methods: In 2011 a feasibility study about the number of GC patients was run 
in the sites of 63 oncologists, 23 hemato-oncologists and 26 internists in UK (16), 
GER (19), FR (11), IT (27), ES (27), and US (12). Physicians reported about the number 
of “new patients with unresectable, locally advanced or metastatic gastric or gas-
troesophageal junction (GEJ) adenocarcinoma”. The willingness of these specialist 
groups to participate in clinical phase III/IV or health outcome studies was also 
estimated in a different survey. Results: In total these 112 specialists have seen 
approximately 3,200 new gastric cancer patients in the last 6 months. In average 
(median values) oncologists have seen 30 new gastric cancer patients in 6 months, 
hematologists 20 patients and internists 6 patients. Most of the patients (2,600) have 
been treated with chemotherapy. Approximately 90% of the oncologists/hematolo-
gists and 88% of the cardiologists are experienced in clinical phase III/IV or health 
outcome studies; 80% of the oncologists/hematologists and 60% of the cardiologists 
are willing to participate in future studies and 92% resp. 94% in this group are willing 
to enroll patients for clinical phase III/IV or health outcome studies and ask them for 
written informed consent. ConClusions: Patients suffering from Gastric Cancer 
can be successfully recruited for clinical phase III/IV or health outcome studies 
using managed panels. Oncologists/hematologists and cardiologists are usually 
experienced in these studies.
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objeCtives: To investigate differences across randomized controlled trials (RCTs) 
evaluating biological therapies for the treatment of moderate to severe chronic 
plaque psoriasis in terms of baseline risk in psoriasis area severity index score (PASI) 
and the association with treatment effects by means of network meta-analysis 
(NMA). Methods: 25 RCTs reporting the proportion of patients experiencing a 
0.2). However, absolute risk reduction was generally higher in high risk strata, 
ranging from -1.4 to 18.3% (median= 4.6%; IQR= 0.8-6.1%) in quartile one and from 
0.8 to 35.0% (median= 11.5%; IQR= 3.3-19.8%) in quartile four. The difference in 
the absolute risk reduction between the extreme risk quartile ranged from -3.2 to 
28.3% (median= 7.7%; IQR= 0.3-11.3). ConClusions: Clinically significant HTE is 
common even in phase 3 “efficacy” trials on the absolute scale. A multivariate risk 
stratified approach to subgroup analysis is feasible and often clinically informative 
when assessing treatment efficacy.
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objeCtives: Cost-effectiveness models are an important component of health 
economic evaluation. In addition to estimates of treatment effects (typically 
estimated for RCTs), cost-effectiveness estimates may be sensitive to estimates of 
non-treatment specific parameters that describe the relationship between model 
variables. These may be estimated from epidemiological studies that themselves 
include covariable adjustment in order to account for potential confounding. We use 
the example of the estimated relationship between BMI and utility as to illustrate 
methods for the review meta-analysis of parameter estimates arising from multi-
ple studies and issues around the selection of appropriate estimates. Methods: 
A targeted search was carried out in MEDLINE and EMBASE for studies with utility 
data on BMI. The outcome was utility change per unit increase in BMI. Study charac-
teristics recorded included the utility instrument used, study location, diabetes sta-
tus and number of covariates. Fixed and random effects models as well as graphical 
methods were used to investigate the influence of study characteristics. Results: 
Several utility scales were used throughout with some using multiple utility scales 
within the study to assess quality of life. EQ5-D and SF-6D were the most com-
monly used utility scales. Using a random effects model we observed a change 
in utility per unit increase in BMI of -0.0054 [-0.0077; -0.0031]. However there was 
significant heterogeneity between studies. The number of covariates ranged greatly 
between the studies and appeared predictive of the magnitude of effect of BMI on 
utility. ConClusions: We illustrate methods for meta-analysing multiple param-
eter estimates and discuss the selection of appropriate parameter estimates for the 
inclusion in cost-effectiveness models. In particular we illustrate the relationship 
between the selection of appropriate parameter estimates in terms of which covari-
ables were included in the originating studies and the cost-effectiveness model 
structure in terms of which independent causal effects are modelled.
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objeCtives: This research was conducted to understand key reasons why the G-BA 
came to a different benefit rating than IQWiG during oncology HTAs. Methods: 
Searching the G-BA and IQWiG homepages, oncology HTAs between 1st of January 
2011 and 31st of December 2013 have been identified. Assessments for which the 
G-BA attested a benefit rating divergent from the one proposed by IQWiG have been 
analyzed to reveal the key reasons for difference. Results: In the observed time 
frame, 18 HTAs of oncology products have been conducted by IQWiG and G-BA in 
Germany. IQWiG and G-BA were aligned in their benefit ratings in 14 reports (78%). 
During four assessments (22%) the G-BA came to a different conclusion than IQWiG. 
These are the assessments of crizotinib, eribulin, pertuzumab and the resubmission 
for vandentanib. One reason for different ratings observed in three assessments 
is that the G-BA looked at time-adjusted analyses to correct for different lengths 
of treatment in the trial arms. The extend of benefit that is extracted from the 
same data also potentially differs. This is exemplified by the case of vandentanib, 
where the G-BA was more convinced by the data on “time to worsening of pain” 
than IQWiG and attested a “minor benefit” (as compared to “no added benefit”). 
In the case of eribulin, G-BA and IQWiG agreed on benefit based on survival data. 
Due to the potential side effects however, G-BA demoted to “minor”, while IQWiG 
initially demoted to “no added benefit”. ConClusions: The translation of clinical 
evidence into a benefit rating and weighing of positive versus negative effects is 
highly complex. We see that G-BA and IQWiG can come to different conclusions. In 
all cases it is important that the manufacturer shows evidence against the speci-
fied comparator. The benefit rating plays an important role in the reimbursement 
amount negotiations.
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suRViVal status in (PHaRMaco) ePideMiological studies can be 
successfully inVestigated using adMinistRatiVe Residential 
RegistRies
Potthoff P., Eichmann F., Klamert A.
Kantar Health Germany, Munich, Germany
objeCtives: Study subject survival is a key outcome and endpoint in pharmacoepi-
demiological studies. When participants in long-term studies drop out, administra-
tive residential registries can be a useful source to investigate subjects’ vital status. 
The present contribution reports procedures and results of vital status inquiries 
in German administrative residential databases. A pharmacoepidemiological and 
an environmental exposure study are used as case studies. Methods: For both 
case studies, residential addresses of study participants were submitted to the 
responsible official residential register with the purpose of collecting information 
about vital status or – in case of address changes – the new address was collected. 
For persons with multiple address changes up to 7 inquiry loops were necessary 
until vital status could be ascertained. Results: In the environmental case study 
assessing effects of an urban chemical accident, 20.170 addresses of German citizens 
